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Contre le développement des Bactéries Multi-résistantes (AC-de-BMR)Summary
Resistance to antibiotics has increased recently to a dramatic extend, and the pipeline of new antibiotics is almost
dry for the five next years. Failures happen already for trivial community acquired infections, like pyelonephritis, or
peritonitis, and this is likely to increase. Difficult surgical procedures, transplants, and other immunosuppressive
therapies will become far more risky. Resistance is mainly due to an excessive usage of antibiotics, in all sectors,
including the animal one. Action is urgently needed. Therefore, an alliance against MDRO has been recently
created, which includes health care professionals, consumers, health managers, and politicians. The document
highlights the different proposed measures, and represents a strong consensus between the different professionals,
including general practicionners, and veterinarians.After saving countless lives, antibiotics are in danger of
losing their effectiveness[1]. The reason is an alarming
increase in bacterial resistance combined with a decline
in the antibiotic pipeline flow. Treatment failures are
already occurring in patients with infections whose only
unusual feature is causation by multidrug-resistant (MDR)
bacteria, some of which are capable of resisting all the
available antibiotics [2]. These failures will become in-
creasingly common, and some of them will result in life-
threatening situations. In addition, risks will increase
sharply in patients who require procedures associated
with a high risk of infections (e.g., major surgery, organ
transplantation, and immunosuppressive treatments).
Antibiotics are unique medications in that their targets
(bacteria) are living organisms capable of adapting by
developing mechanisms that confer resistance to antibio-
tics (e.g., mutations and the acquisition of resistance-
gene vehicles). Despite this feature shared by no other
medication, antibiotic prescription is viewed as a trivial
act, both in humans and in animals. Limited improve-
ments have been achieved, but France remains among
the heaviest consumers of antibiotics in Europe.
Clearly, there is a pressing need to protect the effect-
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reproduction in any medium, provided the orin general) via proactive strategies similar to those used
to save endangered species, in keeping with the concept
of sustainable development. Antibiotics are unique med-
ications and must be prescribed only with good reason.
Each prescription should be thought carefully, and the
short-term benefits to the patient (which obviously de-
serve priority in the event of a bacterial infection) should
be weighed against two categories of deleterious effects:
short-term adverse effects on the patient – such as man-
ifestations of intolerance or allergies, which are unaccept-
able if the antibiotic is not indispensable – and negative
medium-term effects on bacterial ecology, with selection
of MDR organisms. Selected MDR organisms subse-
quently cause infections in the community, of which the
patient is a member. The prescription of antibiotics must
be the result of a complex deliberative process, whose
components must obey evidence-based rules. This object-
ive of achieving rational antibiotic prescribing practices
requires an orchestrated effort by both the healthcare
system users and the prescribers. Other strategies should
be implemented concomitantly, such as campaigns to
promote immunizations known to exert antibiotic-sparing
effects (e.g., against influenza, measles, and pneumococ-
cal pneumonia).
The World Alliance against Resistance to antibiotics
(WAAR) is a crosscutting action plan designed by a small
group of professionals and by the patient-support grouptd. This is an Open Access article distributed under the terms of the Creative
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involves healthcare providers (in hospitals and private
practice), veterinary medicine professionals, and the food
industry. It is of immediate significance for current and
future users of the healthcare system, as well as for all
citizens.
The Alliance is a group of about 350 individuals repre-
senting all the key stakeholders including healthcare
system users (LIEN, CISS, Patients for Patient Safety
[WHO], and the Association for the defense of Victims
of Nosocomial Infections [ADVIN] in Quebec). The sci-
entific committee is composed of 80 international physi-
cians of considerable renown. The Alliance receives
support from 50 learned societies or professional groups
in France and throughout the world. It is a nonprofit
organization (French law of 1901) open to professionals
and users worldwide.
SAFEGUARDING ANTIBIOTICS requires an orche-
strated effort carried out jointly by healthcare system
users and prescribers (in the broad sense of the term).
Therefore, WAAR has chosen as its primary objective to
raise awareness among all stakeholders of the urgency
and magnitude of the threat. WAAR must lobby actively
for antibiotics beyond the circle of insiders in order to
raise awareness among policy-makers, international health
organizations (WHO, World Organization for Animal
Health, European Centre for Disease Prevention and
Control), and the entire population. The Alliance, in
France is designed to serve as a complement to two
French nationwide programs, the Antibiotic Alertness
Program for 2011–2016 and the Antibiotic Resistance
Minimization in Veterinary Medicine Program. The Alli-
ance has no conflicts of interest.
WAAR advocates a number of immediate measures:
 a much more cautious and controlled approach to
the use of antibiotics, in all areas;
 relentless efforts to prevent the cross-transmission
of MDR organisms both in hospitals and in private
practice;
 the expansion of basic and applied research efforts
in human and veterinary medicine;
 the development of new antibiotics, including via
the identification of methods based on antiadhesion
molecules to combat specific bacterial species;
 the development of antibiotics or treatment
strategies for veterinary medicine that have the
smallest possible ecological impact;
 the development of new vaccines;
 a much more widespread use of diagnostic tests,
with the goal of limiting the prescription of
antibiotics to proven bacterial infections;
 a ban of broad spectrum antibiotic use without an
attempt to diagnose the cause of the infection increased surveillance of antibiotic resistance and
use, with regular feedback to healthcare
professionals and the public;
 education and training programs for healthcare
professionals and consumers;
 the rapid implementation of antibiotic programs for
humans and animals, by making the necessary
resources available.
Some of these measures are part of the Antibiotic
Alertness Program for 2011–2016 implemented by the
French National Health Agency (Direction Générale de
la Santé, DGS) and of the Antibiotic Resistance Min-
imization in Veterinary Medicine Program. However, the
Alliance advocates much stronger measures to be imple-
mented on an emergency basis, most notably regarding
the modalities of antibiotic prescription.
Detail of the measures advocated by the Alliance
A vast information campaign
A vast information campaign on antibiotics targeting
physicians, veterinarians, pharmacists and consumers is
needed to raise awareness of the threat to the life-saving
potential of antibiotics. Consumers must be reminded
that antibiotics have no effect on viruses, which account
for the overwhelming majority of respiratory tract infec-
tions. Both physicians and consumers should feel ac-
countable whenever an antibiotic is prescribed. The
French public health insurance system (Caisse Nationale
d’Assurance maladie, CNAM) is currently conducting an
information campaign. This measure needs to be inten-
sified, and information efforts must be thought through
and developed in partnership with the key stakeholders,
in a manner that is consistent with other components of
the strategy for safeguarding antibiotics. The information
campaign targeting healthcare professionals and con-
sumers should include advice on basic hygiene and on
the prevention of cross-transmission. These two topics
should be dealt with in a well-orchestrated manner.
Prescribing antibiotics in a reasoned manner, in hospitals
and in private practice, in humans and in animals
Structural measures
 Hospital physicians with specific training in
antibiotic stewardship should be given a greater role.
A decree is needed to specify their status, mission,
and training; appropriate ratios; and funding modalities.
 Infectious-diseases and medical-microbiology
networks linking private practice physicians and
hospitals should be created. Centers supplying
advice on antibiotic treatment and ensuring the
surveillance of bacterial resistance patterns in
private practice, hospitals, and medical-social
Carlet et al. Antimicrobial Resistance and Infection Control 2012, 1:25 Page 3 of 6
http://www.aricjournal.com/content/1/1/25institutions should be set up as part of these
networks, in connection with a reference hospital
(similar to Medqual in the Loire region, Antibiolor
in Lorraine, and Primair in Franche-Comté). Each
center should have a telephone hotline for hospitals
and another for private practices. Both hotlines
should be operated by paid professionals. Thus,
each region of the country should have a network of
well-trained antibiotic stewards who can provide
advice by telephone around the clock 7 days a week
to healthcare facilities that have no antibiotic
stewards on their staff.
 Awareness of these networks and antibiotic stewards
should be increased via vast communication
campaigns targeting professionals, and incentives to
encourage the use of these networks should be
provided.
 The entire process of antibiotic prescription and
delivery to each patient identified by name should
be entered into secure databanks.
 Decision-making aids complying with suppress french
recommendations should be widely disseminated
(e.g., www.antibioclic.com).
 A number of antibiotics should be reserved for use
in humans (e.g., carbapenems and new antibiotics
developed for humans), and restrictions should be
placed on the use in animals of antibiotics that are
critical to humans (cephalosporins and
fluoroquinolones) (Reference 26 of the veterinary
medicine program).
 A study should be conducted to evaluate the
prescription and delivery of antibiotics by
veterinarians and the consequences on antibiotic
consumption. European directives must be
developed promptly to revise marketing practices
related to the promotion and sales of antibiotics
(reference 29 of the veterinary medicine program).
 A vast program of university training and continuing
education for professionals should be set up.
Curricula for human and animal healthcare
professionals should give priority to the wise
use of antibiotics and to good hygiene practices,
most notably those designed to limit the
cross-transmission of microorganisms. In these
areas, measures designed to modify current
practices should receive recognition (P4P?).
 The European program e-bug (www.e-bug.eu)
designed to raise awareness of these objectives
among schoolchildren should be widely advertised.
Technical measures
 Each hospital should have a list of antibiotics whose
use must be approved by an antibiotic steward(although the first few doses would be available
immediately to avoid treatment delays)
 Each antibiotic prescription to hospital patients
should require validation by a senior physician.
 An attempt to isolate a microbiological pathogen
needs to be undertaken for all patients that receive
broad spectrum antibiotics
 Generic drugs should be used only if they have been
proven as effective as the corresponding proprietary drugs.
 Preference should be given to antibiotics that have
limited ecological effects, and the most recent
antibiotics should be used rationally.
 Antibiotic treatment durations should be kept as
short as possible, and when appropriate antibiotics
should be stopped after a careful reappraisal
(based on the clinical course and new results from
the microbiology laboratory).
 Antibiotics should be delivered only in the
amount prescribed (if need be, by delivering only
part of the contents of the package) to minimize
self-medication; this measure has already been
adopted in other countries.
 A specific prescription form should be developed for
antibiotics at high risk for inducing ecological
effects, such as third-generation cephalosporins,
fluoroquinolones, and carbapenems.
 The measures taken for human medicine should be
adapted to veterinary medicine, based on the
specific features of animal care. Routine prophylactic
antibiotic treatment of livestock and fish must be
prohibited, except when the presence of risk factors
has been documented. After the onset of an outbreak
in a farm, early prophylactic antibiotic treatment of all
animals or metaphylactic antibiotic treatment of
selected subgroups may be in order. Only the amount
of antibiotics corresponding to the prescription should
be delivered. The treatment should be brief, in order
to minimize its ecological impact. The price or price
margin of veterinary antibiotics should be set
according to the benefits they produce.
A measure of considerable symbolic impact would consist
in having the UNESCO include antibiotics on the World
Heritage list
Effective antibiotics are an endangered species, and their
use should be subsumed to ecological principles and
integrated within a global sustained development con-
cept. Because they of considerable universal value, anti-
biotics deserve to be protected.
Preventing cross-transmission and selection pressure
Cross-transmission
The health threats due to fecal contamination with
MDR bacteria require vigorous action. Under everyday
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occurs chiefly via the hands. Hand hygiene practices
must be improved in the community across the range of
social activities. For example, individuals must learn to
sneeze and cough into the crook of the elbow if im-
mediate hand disinfection is not possible. The use of
hydroalcoholic hand rubs should be encouraged in
healthcare settings and, under some circumstances, in
the community.
Hospitalized patients known to carry MDR bacteria
should be isolated. In addition, patients with risk factors
such as multiple hospital admissions, medical evacuation
from abroad, and hospital admission abroad within the
past year should be screened and isolated until the
results are available. The best course of action may vary
across MDR organisms. More generally, strict adhesion
to standard hygiene recommendations is crucial with all
patients.
In livestock farms, good hygiene and appropriate facil-
ities and practices are indispensable. Hygiene is critically
important wherever animals are raised.
Minimizing ecological effects
Waste products from hospitals and livestock farms
should be processed appropriately. There is a need for
rethinking waste treatment plant operations in order to
prevent contamination of soil and water, as antibiot-
ics continue to select MDR organisms in the natural
environment.
Resources should be made available to improve the de-
tection of resistant bacteria in drinking water and in
foods such as meat and fish.
Supporting research
 Intensified research efforts are needed to elucidate
the epidemiological mechanisms underlying bacterial
resistance and to develop new antibiotics, new
vaccines, and non-antibiotic anti-infectious agents
for use in human and veterinary medicine. Research
into the behaviors that explain the greater
consumption of antibiotics in France compared to
other European countries may help to design
effective campaigns targeting prescribers and the
public, with the goal of improving antibiotic usage.
 Financial incentives should be created to support
startup companies focusing on the development of
new products, as well as pharmaceutical companies
exhibiting a firm commitment to a policy of good
antibiotic usage.
Improving the diagnosis of bacterial infections
Existing rapid diagnostic tests (RDTs) should be used
widely and appropriately. They include the rapid streptest for streptococcal pharyngitis and urinary dipstick
tests. In infections of greater severity, such as pneumo-
nia, the C-reactive protein or procalcitonin level can be
measured in a sample of capillary blood collected at the
bedside (although the results must be confirmed). In
many cases, these rapid and simple tests can rule out a
bacterial infection, thereby avoiding the use of antibio-
tics. They should be reimbursed by statutory health in-
surance systems. Support should be provided to the
development of tests characterized by greater specificity
and sensitivity, as well as of multifunction tests.
All these crucial measures are being advocated by pro-
fessionals, and professionals should be in charge of con-
trol processes and training. If these measures are not
taken now, then the near future may witness the imple-
mentation on an emergency basis of compulsory mea-
sures that may be either inappropriate or difficult to
accept.
Enhancing and exploiting surveillance data
Europe has an outstanding system for monitoring anti-
biotic resistance patterns and antibiotic use. However,
further surveillance efforts are needed in the community
and in veterinary medicine. Furthermore, surveillance
data should be communicated in simple terms and at
regular intervals to healthcare professionals, decision-
makers, and the public, both for the entire country and
for each region.
Evaluating the program
The objective of the French nationwide program for
humans and animals is an at least 25% decrease in anti-
biotic consumption over 5 years.
WAAR advocates a 30% decrease over 3 years, in both
humans and animals, to rapidly reach the mean value
for European countries.
In conjunction with hygiene practices in hospitals and
in the community (schools, other institutions, and fam-
ilies), this measure would be expected to stabilize resist-
ance levels at their current values or perhaps even to
obtain a decrease.
WAAR advocates the following resistance indicators
and target values: penicillin-resistant pneumococci (tar-
get, 1%), methicillin-resistant Staphylococcus aureus
(MRSA; target, 10%), Escherichia coli resistant to third-
generation cephalosporins (target, <10%), glycopeptide-
resistant enterococci (VRE) (target, sporadic cases), and
carbapenem-resistant Enterobacteriaceae (CRE) (target,
sporadic cases) this could vary according to countries.
The profile and amount of antibiotics prescribed by
each physician working in office practice is monitored in
France by the statutory health insurance system. The
data thus obtained should provide a tool for physician
self-evaluation and quality-indicator development.
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pened, in particular by factoring in the profile of each
physician’s patient caseload. One approach may be to
have professional organizations conduct critical reviews
of random samples of patient files.
Conclusion
To safeguard the small number of antibiotics that are
still effective, and to protect the few antibiotics that will
be introduced in the future, awareness must be raised
throughout the country, on an emergency basis. Prescri-
bers and consumers should work together to achieve this
objective.
JOIN US NOW, by contacting
Jean Carlet, president of WAAR, 9 rue de la terrasse
94000 Créteil, FRANCE
jeancarlet@gmail.cofm.
Your help is vital!!
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Organizations providing active support to the Alliance
Association Le LIEN, Association Le CISS, Fédération des Spécialités Médicales
(FSM), Association pour la chimiothérapie anti-infectieuse (ACAI),Observatoire
National d’épidémiologie de la Resistance Bactérienne aux antibiotiques
(ONERBA),Collège National des Généralistes Enseignants (CNGE),
Collège national de médecine générale (CNMG), Fédération Française de
pneumologie (FFP), Groupe de Pathologie Infectieuse en Pédiatrie (GPIP),
Collège des Enseignants de Maladies Infectieuses (CEMIT), Fédération
Française d’Infectiologie (FFI), Collège National de Pathologie Infectieuse
(CNPI), Institut Maurice Rapin (IMR), Medqual (F. Ballereau), Antibiolor
(C Rabaud), Observatoire du Risque Infectieux en Gériatrie (ORIG, Réseaux de
surveillance des antibiotiques et des bactéries multi-résistantes du Sud Est),
Le Forum des bio-hygiénistes, Arab Alliance for a prudent use of
antimicrobials (Ar-Apua), Association Phagespoir, Programme National de
lutte contre l’infection nosocomiale (PRONALIN, Senegal), Réseau
International pour la Planification et l’Amélioration de la Qualité, et de la
Sécurité dans Services de Santé en Afrique (RIPAQS), Infection Prevention
and Control African Network (IPCAN), Association des médecins
coordonnateurs en EHPAD, Association de Lutte contre les Infections
Associées aux Soins (ALIAS), Ligue Africaine des Associations pour la Sécurité
des patients (LIASEP), Portuguese alliance for the preservation of the
antibiotic, ESGAP working group (ESCMID), and Association des victimes
d’infection nosocomiale (ADVIN).
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